Mesalamine most commonly prescribed Crohn’s disease treatment among older patients

SAN ANTONIO — Older patients with Crohn’s disease were less likely to receive biologic agents and more than twice as likely to receive mesalamine compared with younger patients, according to data presented at the American College of Gastroenterology Annual Meeting.Researchers observed these findings from data on patients enrolled in TARGET-IBD, an observational cohort of more than 3,000 patients with inflammatory bowel disease receiving usual care at 34 community and academic practices across the United States.“The idea behind the cohort is to follow patients over time so weRead More

Share on facebook
Share on twitter
Share on linkedin